Depixus SAS has raised €30.6 million in Series A financing to support development of technology that can extract information from DNA, RNA and proteins, thereby generating new insights into the function of the human genome. The round was co-led by Lansdowne Partners and the PSIM Fund which is operated by Bpifrance on behalf of the French state. The new financing brings the company’s total equity and grant funding to more than €41 million.
